News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary Data from Galera Therapeutics’ Phase 2b Clinical Trial of Avasopasem Manganese (GC4419) Presented at ASTRO Annual Meeting
MALVERN, Penn. — October 23, 2018  — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, announced data from its Phase 2b clinical trial evaluating avasopasem
View HTML
Toggle Summary Galera Therapeutics Announces Dosing of First Patient in Pivotal Phase 3 ‘ROMAN’ Clinical Trial of Avasopasem Manganese (GC4419)
Data from pivotal trial of avasopasem manganese for the reduction of severe oral mucositis in patients with head and neck cancer intended to support New Drug Application MALVERN, Penn. — October 15, 2018 —  Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development
View HTML
Toggle Summary Galera Therapeutics Raises $150 Million for GC4419 Phase 3 Trial and Pre-Commercialization Activities in Lead Indication
Pivotal trial of GC4419 for the treatment of severe oral mucositis in patients with head and neck cancer expected to initiate in fourth quarter 2018 MALVERN, Penn. — September 19, 2018  — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting
View HTML
Toggle Summary Galera Therapeutics Presents Structure and Synthesis of GC4419 at American Chemical Society Annual Meeting
Presentation selected as part of The Halpern Legacy Symposium and press program Phase 3 trial of GC4419 for treatment of severe oral mucositis in patients with head and neck cancer expected to initiate in fourth quarter 2018 MALVERN, Penn. — Aug. 20, 2018  — Galera Therapeutics, Inc., a
View HTML
Toggle Summary Data from Galera Therapeutics’ 223-Patient Phase 2b Clinical Trial of GC4419 Presented at MASCC/ISOO 2018 Annual Meeting
GC4419 demonstrated clinically significant reduction in duration and incidence of severe oral mucositis (SOM) in patients with head and neck cancer Trial investigator Dr. Carryn Anderson honored with Steven M. Grunberg Memorial Award for excellence in cancer research MALVERN, Penn.
View HTML
Toggle Summary Galera Therapeutics Announces Presentation of Data from Phase 2b Clinical Trial of GC4419 at MASCC/ISOO 2018 Annual Meeting
Abstract receives Steven M. Grunberg Memorial Award for excellence in cancer research MALVERN, Penn. — June 12, 2018  — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer
View HTML
Toggle Summary Data from 223-Patient Phase 2b Clinical Trial of Galera Therapeutics’ GC4419 Presented at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
GC4419 met primary endpoint, achieving 92 percent reduction in duration of severe oral mucositis (SOM) in patients with head and neck cancer GC4419 also demonstrated reduction in SOM incidence and severity, and was well tolerated Abstract to be featured in 2018 Best of ASCO program​​​​​​​ MALVERN,
View HTML
Toggle Summary Galera Therapeutics Announces Presentation of Data from Phase 2b Clinical Trial of GC4419 at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Data demonstrate GC4419 reduced duration, incidence and severity of radiation-induced severe oral mucositis in patients with head and neck cancer Abstract selected for 2018 Best of ASCO program MALVERN, Penn. — May 16, 2018  — Galera Therapeutics, Inc., a clinical-stage biotechnology company
View HTML
Toggle Summary Galera Therapeutics Announces Preclinical Data Demonstrating Potential of GC4419 to Improve Effectiveness of Radiation While Preventing Normal Tissue Toxicity
Posters presented at 2018 American Association for Cancer Research Annual Meeting MALVERN, Penn. — Apr. 16, 2018  — Galera Therapeutics, Inc., a clinical-stage biotechnology company developing drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, today
View HTML
Toggle Summary Galera Therapeutics Receives FDA Breakthrough Therapy Designation for GC4419 for the Reduction of Severe Oral Mucositis
Designation Based on Positive Results of Phase 2b Trial of GC4419 Severe Oral Mucositis Affects 70 Percent of Head & Neck Cancer Patients Receiving Radiotherapy MALVERN, Penn. — Feb. 28, 2018  — Galera Therapeutics, Inc., a clinical-stage biotechnology company developing drugs targeting oxygen
View HTML